At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 658 enrolled
Drug / intervention
Cabozantinib tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
In Brief
A Phase 3 clinical trial evaluating Cabozantinib tablets and Everolimus (Afinitor) tablets for Renal Cell Carcinoma. Completed, enrolled 658 participants across 205 sites in 26 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesArgentina, Australia, Austria, Belgium, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartJun 2013
Primary CompletionMay 2015
Study CompletionJan 2021
TodayJul 2026
First PostedMay 31, 2013
Enrollment StartJun 1, 2013
Primary CompletionMay 22, 2015
Study CompletionJan 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 13.1 years ago
Interventions
Cabozantinib tabletsdrug
Everolimus (Afinitor) tabletsdrug